Quanterix Corporation QTRX
At closeNov 4, 2026, 4:47 AM EST
Pre-market · Nov 4, 4:47 AM ET
- YTD
- -53.77%
- 1 year
- -44.42%
- Market cap
- 139.04M
- Revenue (ttm)
- 129.33M
- Profit margin
- -30.71%
- EPS (ttm)
- -2.74
- Shares out
- 38.38M
- Forward P/E
- -12.10
- YTD return
- -53.77%
- 1-year return
- -44.42%
- Volume
- 266.87K
- Avg volume
- 752.03K
- Open
- 2.87
- Previous close
- 2.81
- Day's range
- 2.87 – 2.98
- 52-week range
- 2.15 – 8.77
- Beta
- 1.36
- Analysts
- Buy
- Price target
- 21.80 (+641.5%)
- Earnings date
- May 7, 2024
5m +0.06 (+2.08%)
Key statistics
- Enterprise value
- 145.70M
- PEG ratio
- 0.00
- Price / sales
- 3.16
- Price / book
- 1.21
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 10.80%
- Free cash flow
- -24.58M
- Total cash
- 296.86M
- Total debt
- 39.58M
- Return on equity
- -11.48%
- Short % of float
- 5.48%
- 50-day average
- 12.39
- 200-day average
- 14.99
Analyst view
Consensus: buy
- Target (low)
- 16.00
- Target (mean)
- 21.80
- Target (high)
- 28.00
- Strong buy2
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
May 7, 2024
Expected May 7, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 8, 2024 | Jun 1, 2024 | -0.23 | -0.25 | -0.02 | -8.70% |
| May 7, 2024 | Mar 1, 2024 | -0.33 | -0.26 | +0.07 | +21.21% |
| May 7, 2024 | Mar 1, 2024 | -0.33 | — | — | — |
| Feb 29, 2024 | Dec 1, 2023 | -0.28 | — | — | — |
| Feb 29, 2024 | Dec 1, 2023 | -0.28 | -0.33 | -0.05 | -17.86% |
| Nov 6, 2023 | Sep 1, 2023 | -0.35 | -0.21 | +0.14 | +40.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 2024 | TD Cowen | main | Hold | Hold |
| Aug 12, 2024 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Aug 9, 2024 | TD Cowen | main | Hold | Hold |
| Jul 9, 2024 | Goldman Sachs | main | Buy | Buy |
| Apr 29, 2024 | Canaccord Genuity | main | Buy | Buy |
| Mar 4, 2024 | Scotiabank | main | Sector Outperform | Sector Outperform |
About Quanterix Corporation
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- quanterix.com
News
Head-To-Head Comparison: Quantum-Si (NASDAQ:QSI) vs. Quanterix (NASDAQ:QTRX) 
Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026 
TD Cowen Maintains Hold on Quanterix, Raises Price Target to $3.5 
Quanterix, Innovita Biological Technology Receives Regulatory Nods From China For Quanterix SIMOA Technology, Neurology Biomarker Testing
Your note
Sign in to keep a note on QTRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DONNELLY WILLIAM P | Director | Stock Award(Grant) | Sep 30, 2024 | 34,583 |
| ELLIOTT JEFFREY THOMAS | Director | Stock Award(Grant) | Aug 18, 2024 | 11,985 |
| HLAVINKA SARAH E | Director | Stock Award(Grant) | Sep 30, 2024 | 46,001 |
| MADAUS MARTIN D PH.D. | Director | Stock Award(Grant) | Jan 1, 2024 | 284,106 |
| MAGOVCEVIC-LIEBISCH IVANA | Director | Stock Award(Grant) | Oct 1, 2024 | 12,800 |
| MEISTER PAUL M | Director | Stock Award(Grant) | Sep 30, 2024 | 295,729 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Alliancebernstein L.P. | 8.51% | 3,265,603 | 34.78M | Sep 29, 2024 |
| Blackrock Inc. | 8.37% | 3,210,916 | 34.20M | Sep 29, 2024 |
| Portolan Capital Management, LLC | 6.57% | 2,520,686 | 26.85M | Sep 29, 2024 |
| Vanguard Group Inc | 5.73% | 2,197,839 | 23.41M | Sep 29, 2024 |
| Millennium Management Llc | 5.37% | 2,062,132 | 21.96M | Sep 29, 2024 |
| Ameriprise Financial, Inc. | 3.95% | 1,517,248 | 16.16M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AB Cap Fd.-AB Small Cap Growth Port | 4.56% | 1,748,336 | 18.62M | Oct 30, 2024 |
| Fidelity Rutland Square Tr II-Strategic Advisers U.S. Total Stock Fd | 3.88% | 1,488,466 | 15.85M | Oct 30, 2024 |
| Fidelity Strategic Advisors Small-Mid Cap Fund | 3.39% | 1,299,661 | 13.84M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.99% | 1,148,775 | 12.23M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.41% | 926,529 | 9.87M | Oct 30, 2024 |
| Principal Small Cap Growth Fd I | 1.71% | 656,055 | 6.99M | Jul 30, 2024 |